Best Diabetes Drugs for Weight Loss: Semaglutide, Tirzepatide, and Metformin Compared

No diabetes medicine is best for weight loss for everyone. For adults with type 2 diabetes and overweight or obesity, GLP-1–based medicines such as semaglutide and the dual GIP/GLP-1 medicine tirzepatide may support weight management, but the right choice also depends on glucose goals, health history, risks, access, and clinician review 1 2.

How did we evaluate diabetes drugs for weight loss?

We ranked these options by the strength of human evidence for body-weight change, their role in type 2 diabetes care, known safety limits, and the need for clinician oversight. Randomized trials matter because they can separate a medicine’s effect from changes that may happen for other reasons.

Weight change alone does not decide whether a medicine fits. A clinician should also consider hemoglobin A1C, blood-glucose patterns, current medicines, kidney function when relevant, nutrition, muscle preservation, and whether someone has a condition that makes a medicine unsuitable 1 5.

1. Is semaglutide the best-supported option for weight management?

Semaglutide is the best-supported option in the randomized weight-management studies included here. It is a GLP-1 receptor agonist. Brand-name semaglutide products include Ozempic, Wegovy, and Rybelsus, each with its own FDA-approved labeling and uses 1 6.

In STEP 8, adults with overweight or obesity without diabetes receiving weekly subcutaneous semaglutide had greater weight reduction than participants receiving daily liraglutide over 68 weeks 3. In STEP 5, semaglutide-associated weight loss was sustained through 104 weeks in the trial population 7. Individual results vary.

• Best for: adults whose clinician believes a GLP-1 receptor agonist fits both metabolic and weight-management goals.
• How it works: GLP-1 signaling can affect appetite, food intake, gastric emptying, and glucose-dependent insulin secretion 8.
• Key limitation: nausea, vomiting, diarrhea, constipation, abdominal pain, and dehydration can occur; the FDA label also includes important warnings and contraindications 1.
• Important context: evidence from FDA-approved products and clinical trials does not establish results for compounded formulations.

Semaglutide is not a universal choice. Its FDA labeling lists situations where it should not be used, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 for certain labeled products 1. A licensed prescriber should review these risks before starting or changing treatment.

2. When might tirzepatide be a diabetes medicine to discuss for weight loss?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Brand-name tirzepatide products include Mounjaro and Zepbound; their labeled indications are not identical, so a clinician should match the product and treatment goal carefully 2.

Tirzepatide may be a reasonable topic for people with type 2 diabetes and weight-management concerns because it works through two incretin pathways. The supplied evidence set does not include a primary tirzepatide weight-loss trial or a head-to-head tirzepatide-versus-semaglutide trial, so this article does not rank it as superior or provide comparative efficacy numbers.

• Best for: people whose clinician wants to consider a dual GIP/GLP-1 approach within a complete diabetes and weight-management plan.
• Diabetes role: FDA-approved brand-name tirzepatide products have labeled uses that include type 2 diabetes treatment or chronic weight management, depending on the product 2.
• Key limitation: gastrointestinal adverse effects, dehydration risk, and other warnings in the prescribing information still need careful review 2.
• Hypoglycemia risk can rise when tirzepatide is used with insulin or an insulin secretagogue such as a sulfonylurea 2.

For more on safe access and what a legitimate online evaluation involves, see our guide to the best way to get tirzepatide online.

3. Can metformin help with weight loss?

Metformin is an established medicine for type 2 diabetes and may lead to modest weight loss for some people. It is not a GLP-1 medicine, and it does not work by the same appetite-signaling pathway as semaglutide or tirzepatide 4 5.

In the Diabetes Prevention Program, participants assigned to metformin had an average weight loss of about 2.1 kg over 2.8 years, compared with 0.1 kg in the placebo group; the intensive lifestyle group lost more on average 4. That result does not predict what any one person will experience.

• Best for: people for whom metformin fits their glucose-management plan and kidney function.
• Potential advantage: decades of clinical use and an oral formulation 5.
• Key limitation: average weight change is generally modest compared with the semaglutide trial findings discussed above 3 4.
• Safety considerations: gastrointestinal symptoms are common, and kidney function affects whether metformin is appropriate 5.

Our detailed guide to metformin for insulin resistance explains where metformin may fit and why lab review matters.

How do semaglutide, tirzepatide, and metformin compare for weight loss?

The clearest difference is mechanism. Semaglutide and tirzepatide work through incretin-hormone pathways, while metformin mainly improves glucose handling through different metabolic effects 1 2 5.

If preserving strength and lean mass is part of your goal, medication conversations should also include protein intake, resistance training when appropriate, and monitoring. Read more about GLP-1 medicines and muscle loss.

Is Ozempic better than metformin for weight loss?

For weight change alone, the semaglutide trials discussed above showed larger average reductions than metformin showed in the Diabetes Prevention Program. But weight change is only one outcome, and Ozempic and metformin have different FDA-approved uses, risks, routes, costs, and clinical roles. Ozempic is not FDA-approved for weight management 1 3 4.

Ozempic is a brand-name semaglutide product with an FDA-approved type 2 diabetes indication. It is not automatically “better” for a given person. For example, a clinician may prioritize glucose goals, kidney function, gastrointestinal tolerance, other medicines, and insurance or cash access before selecting or changing a treatment 1 5.

Why can diabetes medicines affect appetite and body weight?

GLP-1 receptor agonists can influence several systems at once. GLP-1 signaling can increase glucose-dependent insulin secretion, influence appetite regulation in the brain, and slow gastric emptying, meaning food may leave the stomach more slowly 1 8.

In a randomized study, weekly semaglutide was associated with lower energy intake and changes in appetite and eating control in adults with obesity 8. These effects can also contribute to nausea or early fullness, which is why side-effect monitoring belongs in the same conversation as possible benefits.

Which diabetes medicines can cause weight gain instead?

Some diabetes medicines can be associated with weight gain, particularly insulin and insulin secretagogues such as sulfonylureas. Hypoglycemia prevention can also shape food intake and treatment decisions, especially when medicines are combined 1 2.

This does not mean these medicines are wrong choices. Insulin can be essential care for many people. The practical point is that weight goals should be discussed alongside A1C, glucose readings, low-blood-sugar risk, and the reason each medicine is being used.

What side effects and safety issues should patients consider?

All three options need an individualized safety review. Gastrointestinal adverse effects are common with GLP-1–based medicines and may include nausea, vomiting, diarrhea, constipation, and abdominal discomfort 1 2.

Gastrointestinal effects and dehydration risk

Vomiting or diarrhea can contribute to dehydration. Contact a clinician promptly for persistent vomiting, inability to keep fluids down, severe abdominal pain, or symptoms that feel urgent. FDA-approved product labels contain additional warnings, including pancreatitis-related and gallbladder-related concerns that require clinical assessment 1 2.

Hypoglycemia risk when medicines are combined

GLP-1–based medicines have a greater hypoglycemia concern when used with insulin or a sulfonylurea. This is one reason people should not independently combine, switch, or change doses of diabetes medicines 1 2.

What older adults should discuss with their clinician

Older adults may have more medicines, changing kidney function, nutrition concerns, or a higher consequence from dehydration or low blood sugar. A clinician can review the whole medication list and monitoring plan rather than making decisions based on age alone 1 5.

What happens to weight after stopping a GLP-1 medicine?

What happens to weight after stopping a GLP-1 medicine can vary and should be part of a prescriber-led long-term plan. Long-term planning matters: STEP 5 showed sustained semaglutide-associated weight loss during continued treatment through 104 weeks, but it did not establish what will happen for every person after discontinuation 7.

If you are considering stopping a medication because of cost, side effects, pregnancy plans, a procedure, or another reason, talk with the prescriber first. See our patient guide to getting an Ozempic prescription online for more context on clinical evaluation and follow-up.

Who may be a candidate for medication-supported weight management?

Medication-supported care may be worth discussing for adults with overweight or obesity, especially when metabolic risks such as type 2 diabetes are also present. Clinical eligibility is not based on a single number; it requires a review of health history, contraindications, current medicines, treatment goals, and the labeled use of the medicine being considered 1 2.

People with type 1 diabetes need particularly careful specialty evaluation. Semaglutide has been studied in adults with type 1 diabetes and obesity, but that study should not be generalized into a treatment recommendation for everyone with type 1 diabetes 11.

What does weight-loss treatment at Chia look like?

At Chia, 100% online care starts with a short health questionnaire. A licensed US provider reviews your information and prescribes only where clinically appropriate; a prescription is never guaranteed. Our providers consider your health history, goals, current medicines, and safety factors before deciding whether a treatment path may fit.

We offer compounded semaglutide by injection and compounded tirzepatide as tablets or injection. Both have provider-guided dosing, and microdosing plans may be available when clinically appropriate. Medications are compounded in the United States by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved.

These compounded preparations are not FDA-approved and are not the same as, equivalent to, or interchangeable with Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. If cost is a major concern, our guide to the cheapest weight-loss injections without insurance covers questions to compare before choosing care.

What questions should you ask before choosing a diabetes medicine for weight loss?

Bring practical questions to the visit. A1C and safety goals deserve as much attention as the number on the scale.

1. 1What is the main goal of this medicine: A1C reduction, weight management, cardiovascular risk reduction, or more than one goal?
2. 2Does my diabetes type, kidney function, medical history, or family history affect which medicines are appropriate?
3. 3Could this medicine interact with insulin, a sulfonylurea, or another current medication?
4. 4Which side effects should prompt a call, and how will we monitor hydration, nutrition, and glucose?
5. 5What happens if I cannot tolerate the medicine, cannot access it, or want to stop it?
6. 6If I am considering a compounded preparation, what does FDA approval mean, and what pharmacy and clinician safeguards are in place?

Keep reading

Weight Loss

GLP-1 Dosage for Weight Loss: Starting Doses, Titration, and Maintenance

Weight Management

How to Get a GLP-1 Online Without Insurance

Peptides

NXP 2P Peptide vs Tirzepatide: Evidence, Safety, and Legal Access